Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The rest of the story-
http://www.investorplace.com/36611/pfizer-is-top-seed-in-cancer-drug-race/
Aveo Pharmaceuticals (Nasdaq:AVEO) is testing a renal cancer drug with blockbuster potential. However, the company is short on cash and its coffers may run dry before it can get tivozanib to market in 2013. This makes the company an ideal acquisition candidate.
Exelixis (Nasdaq:EXEL) is another takeover target given its potential for financial distress and the promise of it prostate cancer drug cabozantinib.
Investors who believe the past is prologue might want to temper their enthusiasm about companies with cancer treatments. Cancer is an incredibly complicated disease. As one biologist pointed out, it could even be hundreds or thousands of diseases. And the same drug may be effective with one person with a type of cancer and not another.
Always looming, too, is the big question of who’s going to pay for drugs that may cost upward of $50,000 a year and only marginally extend someone’s life.
Pfizer Is Top Seed in Cancer-Drug Race
Several companies are racing for the sector's top payoff
Apr. 11, 2011, 11:40 am EDT | By Barry Cohen, Health Care Writer
By some estimates, the war on cancer has been a colossal flop. But that hasn’t discouraged pharmaceutical companies from continuing to search for effective ways to treat this elusive killer. The financial rewards are too just too attractive.
The challenge for investors is to figure out which company is going to cross the finish line with the big winners.
In terms of sheer size and scope, Pfizer (NYSE:PFE) looks like the No. 1 seed in the cancer research tournament. At its facility in San Diego, the company has some 1,000 researchers devoted to finding and developing new cancer drugs. Its goal is to reach $11 billion in sales of cancer drugs by 2018. That would be more than four times the category’s sales last year of $2.5 billion, which represented only 5% of Pfizer’s revenue.
The company desperately needs a successor to its blockbuster cardiovascular drug Lipitor, which loses patent protection this year.
Perhaps Pfizer has the answer in Crizotinib, one of its more than 20 new tumor-fighting medicines the company is studying. The lung cancer treatment is expected to be the first of three Pfizer cancer drugs submitted for approval this year. Industry analysts say sales of Crizotinib could reach $755 million by 2015.
Amgen (Nasdaq:AMGN), on the other hand, went the acquisition route to get a promising cancer candidate. The company bought privately held BioVex earlier this year, primarily to get its hands on the cancer vaccine OncoVex, which is in the final stages of testing for the treatment of a skin cancer. The drug also is being studied in head and neck cancer.the experimental cancer vaccine Oncovex, is in the final stages of testing usually required for U.S. regulatory approval, for the treatment of a metastatic melanoma, a skin cancer. The drug also is being studied in head and neck cancer, the companiesthe experimental cancer vaccine Oncovex, is in the final stages of testing usually required for U.S. regulatory approval, for the treatment of a metastatic melanoma, a skin cancer. The drug also is being studied in head and neck cancer, the companies
A number of smaller companies are also chasing the proverbial pot of gold. Onyx Pharmaceuticals (Nasdaq:ONXX) saw its share price jump after the FDA said it would fast-track the company’s cancer drug Carfilzomib for treating the second-most common blood cancer, multiple myeloma.
Others with potentially game-changing cancer drugs in their portfolio include:
Ariad Pharmaceuticals (Nasdaq:ARIA), whose ponatinib in a midstage trial as a treatment for two types of blood cancer. Ariad is trying to develop ponatinib as a treatment for patients who are resistant or intolerant to other treatments.
Seattle Genetics (Nasdaq:SGEN) hopes to have approval later this year of its monoclonal antibody brentuximab vedotin that targets Hodgkin lymphoma. About 8,500 cases of Hodgkin lymphoma were diagnosed in the U.S. during 2010 and more than 1,300 died from the disease
Is it obvious that someone with a large pile of shares is pushing down on the share price every time it starts to peek upward or is it much more technical then that?
Is this run-up for real with this volume or a pump?
Aria2010-- "Perhaps another up day on Mon, but Tues may be setting up for a bit of a technical correction post AACR release."
If possible correction around Tuesday, what do the technical readings in your opinion give for a price rang drop?
Thanks
What scenario will bring about a dilution in the future? Could it be cash needs to reimburse the collaboration agreement milestones payments to MolecularMD?
When and what price level would this happen?
How large a dilution--- taking shares to what new $$?
Any thoughts?
Who are the--- "they're"---- that are going to keep this ranged bound for another six months?
Looks like the manipulators are back!!
Is this news going to take us up or down?
UPDATE: Massachusetts' Galvin: Fund Used Inside Info From Expert NetworkLast update: 3/9/2011 1:36:46 PM(Updates with efforts to obtain comment in the sixth paragraph and background from the complaint throughout)
By Liz Moyer
Of DOW JONES NEWSWIRES
NEW YORK (Dow Jones)--Massachusetts' securities regulator moved to shut down a small Cambridge hedge fund Wednesday after charging it and its manager with using an expert consultant to obtain inside information on two pharmaceutical companies. In an administrative complaint, William Galvin, the Secretary of the Commonwealth, charged James Silverman, 43, and his fund, Risk Reward Capital Management, with using the expert network firm Guidepoint Global to get inside information on clinical trials that helped him to "score dramatic returns" for his fund, which had $24 million of assets as of November. Galvin alleged Silverman paid $80,000 a year to retain Guidepoint after losing 16.9% in 2007, his first year of operation. After retaining Guidepoint in early 2008, his fund returned 55% in 2009 and 52% in 2010. Guidepoint was named as a related party in the case and not accused of wrongdoing by Galvin. The allegations involved nonpublic information Silverman received about Ariad Pharmaceuticals Inc. (ARIA) and Questcor Pharmaceuticals Inc. (QCOR), the complaint says. "This case highlights the role of expert consultants in hedge fund investments, a role that can easily evolve into insider trading," Galvin said in a statement Wednesday. A call to Silverman's lawyer wasn't immediately returned. A spokesman for Guidepoint wasn't immediately available. Galvin subpoenaed Guidepoint in November about its dealings with Silverman's fund after the connection between the two firms was uncovered in the Commonwealth's May 2010 books and records examination of the fund. Expert network firms, which match investment professionals with industry insiders for consultations, are in the center of a broad federal investigation into possible insider trading at big mutual and hedge funds. In recent months, the U.S. filed criminal charges against several consultants and employees of an expert-network firm as part of that insider-trading probe. One of those charged was Winifred Jiau, a California technology contractor who has consulted for Guidepoint as well as Primary Global Research, and for Vista Research, which Guidepoint bought in 2009. Another consultant caught up in the investigation is Dr. Yves M. Benhamou, a French physician and expert in hepatitis treatment, who was accused of providing confidential information about a clinical trial to a hedge fund. The Wall Street Journal has reported that Benhamou worked for Guidepoint, which wasn't named in court documents or accused of wrongdoing. The case filed Wednesday in Massachusetts doesn't name the consultants involved, but lists related parties as a doctor working as a Guidepoint consultant specializing in nephrology, or kidney disease, and three other doctors who worked as clinical investigators. Massachusetts says Silverman, who had no prior experience managing a hedge fund before starting it in 2007, met with 225 expert consultants during 2009 and 2010, paying them up to $1,000 an hour. At least 60% of them were clinical trial investigators bound by confidentiality with respect to a clinical trial. Galvin said Guidepoint doesn't consider disclosed conflicts or confidentiality restrictions its consultants may be under before giving clients access to them. The firm puts that responsibility on the consultants themselves, according to the complaint. Guidepoint also doesn't prohibit pharmaceutical-company insiders or clinical-study investigators from participating in consultations with clients on drugs or clinical trials for which they are bound by confidentiality, according to the complaint, which adds Guidepoint has no involvement with the substance of discussions between experts and clients. The complaint also alleges Silverman deleted documents and other records, including notes he feared "crossed the line." -By Liz Moyer, Dow Jones Newswires; 212-416-2512; liz.moyer@dowjones.com (END) Dow Jones NewswiresMarch 09, 2011 13:36 ET (18:36 GMT)
http://custom.marketwatch.com/custom/tdameritrade-com/html-story.asp?guid=%7Bf03396a3-adf7-4e95-8937-01ae57edf2fc%7D
Is this new?
Massachusetts' Galvin Says Fund Used Inside Information From Expert NetworkLast update: 3/9/2011 11:24:41 AM
By Liz Moyer
Of DOW JONES NEWSWIRES
NEW YORK (Dow Jones)--Massachusetts' securities regulator moved to shut down a small Cambridge hedge fund Wednesday after charging it and its manager with using an expert consultant to obtain inside information on two pharmaceutical companies. In an administrative complaint, William Galvin, the Secretary of the Commonwealth, charged James Silverman and his fund, Risk Reward Capital Management, with using the expert network firm Guidepoint Global to get inside information on clinical trials that helped him to "score dramatic returns" for his fund. Galvin alleged Silverman paid $80,000 to retain Guidepoint after losing 16.9% in 2007, his first year of operation. After retaining Guidepoint in early 2008, his fund returned 55% in 2009 and 52% in 2010. The allegations involved non-public information Silverman received about Ariad Pharmaceuticals Inc. (ARIA) and Questcor Pharmaceuticals Inc. (QCOR), the complaint says. "This case highlights the role of expert consultants in hedge fund investments, a role that can easily evolve into insider trading," Galvin said in a statement Wednesday. Galvin subpoenaed Guidepoint in November. Expert network firms are in the center of a broad federal investigation into possible insider trading at big mutual and hedge funds. -By Liz Moyer, Dow Jones Newswires; 212-416-2512; liz.moyer@dowjones.com (END) Dow Jones NewswiresMarch 09, 2011 11:24 ET (16:24 GMT)
http://custom.marketwatch.com/custom/tdameritrade-com/html-story.asp?guid=%7Bb80a668c-3716-46fe-b64c-1a1c8d34b121%7D
Guess I was being wishful, but that belongs at Disneyland. Thanks for the heads up
Has-- "Dr. Berger will hold a 25-minute breakout session immediately following his presentation”.--been stated before?
ARIAD Pharmaceuticals, Inc. has added a news release to its Investor Relations website.
Title: ARIAD to Present at the Barclays Capital 2011 Global Healthcare Conference
Date(s): 8-Mar-2011 7:41 AM
For a complete listing of our news releases, please click here
CAMBRIDGE, Mass., Mar 08, 2011 (BUSINESS WIRE) --
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will
present at the Barclays Capital 2011 Healthcare Conference being held at
the Lowes Miami Hotel in Miami, Florida. Harvey J. Berger, M.D.,
chairman and chief executive officer at ARIAD, will provide an overview
of the Company's strong oncology pipeline and progress on its three lead
compounds on Tuesday, March 15, 2011 at 2:00 p.m. (ET). Dr. Berger will
hold a 25-minute breakout session immediately following his presentation.
The ARIAD presentation will be webcast live and can be accessed by
visiting the investor relations section of the Company's website at http://www.ariad.com/investor.
A replay of the presentation will be available on the ARIAD website
approximately one hour after the presentation and will be archived for
two weeks.
It's so quiet-- is everyone out of town?
Could it have anything to do with whoever has been dumping shares every time the price pokes it's head up a couple of points now for day? It is probably a little discouraging to some jump on the train!
Would be so very NICE if Mr. Berger would through a bone in on days like this, just one of his newsy items from his big speeches at the conferences. May or may not help a day like this but he couldn’t do much worse then the stuff we’re scraping off the bottom of our shoes!!!!!!!!!!!!!!!!
mcbio www.clinicaltrials.gov two new trial were added today on rida. rida with mk-0752 mk2206 and rida with standard chemo for soft sarcoma's
Wouldn't it be cool if there was such a thing as transparency!
Thank You
IIIverson
Asking these questions shows I'm obviously not very stock savvy but hummer me if you will.
You say "Earnings this week will either close the gap" ----
Is that what I see on the chart between 5.05 & 6.31 or something else?
ARIA chart, earnings this week ----
What the likely date?
ARIA chart, earnings this week will ----push us over $7.50 and I would think over $9 also.
Why "over $7.50"?
Why "over $9"?
Do you think the "13th Annual BIO CEO & Investor Conference" will help the price or do as news has mostly done in the past, run the price down?
Thoughts on highs, lows, close?
Thanks
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 13th Annual BIO CEO & Investor Conference being held at the Waldorf=Astoria Hotel in New York City, New York. Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD, will provide an overview of the Company’s robust oncology pipeline and progress on its three lead compounds on Monday, February 14, 2011 at 11:00 a.m. (ET).
The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company's website at http://www.ariad.com/investor.
Thanks doc,
I'm not "going to dog" on you and didn't think I was or mean to. Sorry if I gave you that impression.
Who is flying this submarine??
Is this still just some churning in the $6.35 aria?
Love to have more funds available now- nice opportunity to pick up @6.46
Wont stay here long!!!
Where do they find sellers that dump @ 6.50?
Can you give examples of retails doing that?
Can you explain a little more fully why you think --@3.75???
"ARIA is going to drop a few bucks just like this sometime in the next few weeks."
Trust me.
I have 100k @ 3.75 waiting for that blip. I love my life.
Is it short selling, dilution or what that has flushed the stock price?
Ph3 Ridaforolimus Data for Sarcoma in 1Q11, Jefferies Raises Price Target on ARIAD Pharmaceuticals (ARIA)
January 5, 2011 8:52 AM EST
Jefferies is keeping their Buy rating on ARIAD Pharmaceuticals (NASDAQ: ARIA) as the company's partner, Merck (NYSE: MRK), is going to report their Phase 3 data for ridaforolimus in 1Q11, which experts view has a ~60% probability of success. If successful the firm is predicting a ~$3/sh upside to current valuation and this is done by assigning a 90% probability to their ~$500M WW peak sales estimate in sarcoma in 2020 and 70% probability to their ~$650M in WW peak sales in endometrial cancer in 2020, with 20% royalty on total sales to ARIA, along with $65 million in potential regulatory milestones from Merck. Jefferies is raising their price target on the company to $8 from $6.
For more ratings news on ARIAD Pharmaceuticals click here and for the rating history of ARIAD Pharmaceuticals click here.
Shares of ARIAD Pharmaceuticals closed at $5.10 yesterday, with a 52 week range of $1.79-$4.49.
http://www.streetinsider.com/Analyst+Comments/Ph3+Ridaforolimus+Data+for+Sarcoma+in+1Q11%2C+Jefferies+Raises+Price+Target+on+ARIAD+Pharmaceuticals+%28ARIA%29/6197095.html
Thanks for calling it for what it is. I just posted it because it's floating around on the internet.
By John Dorfman - Jan 2, 2011 6:00 PM PT
Bloomberg Opinion
Unpopular Stocks Can Be Valuable New Friends: John Dorfman
Cancer Drugs
The final spot on the outliers list goes to Ariad Pharmaceuticals Inc., a Cambridge, Massachusetts, company working on small-molecule drugs to treat aggressive cancers. In May, Merck & Co. signed a licensing agreement to sell one of its drugs. Ariad sells for six times earnings.
http://www.bloomberg.com/news/2011-01-03/unpopular-stocks-can-be-valuable-new-friends-commentary-by-john-dorfman.html?cmpid=yhoo
Do you guys have flying saucers parked somewhere?
As simply put as possible, what scenario or circumstances would it take to raise the ugly head of another infusion of dilutive shares? How likely and when would you envision such? -- Any takers??
Thanks
What is the Rida Succeed trial best time frame for results, please? Better yet, a list of all trials and estimated, hoped for time frames for results.
Thanks-
Sorry~
It was just curiosity not discontent with the benefits of this board
Thank You
Can anyone explain how investorshub gives an of bid 4.70 and an ask of 6.00
5.20and 5.27 every where else?
Anyone know why investorshub is showing a $3.93 Bid when I see $5.08 Bid at other sites?
in small words --why is this running up like this?